Mehdi Hamadani
@medihumdani.bsky.social
BMT & Cellular Therapy | Secretary @ASTCT | Co-Chair @ASTCT CoPG | #bmtsm #CARTcell #lymsm | Personal views | Physician not Provider | 🇵🇰 🏏 🇺🇸 🏈
Answer: T-LGL clone. Often donor in origin
- Associated with neutropenia.
- Can be clonal
- rule out viral reactivations (EBV, CMV etc)
- I often treat (in neutropenics) 60mg pred x 10-14days [no taper]
In this patients, post pred the clonal T-LGL diappeared
- Associated with neutropenia.
- Can be clonal
- rule out viral reactivations (EBV, CMV etc)
- I often treat (in neutropenics) 60mg pred x 10-14days [no taper]
In this patients, post pred the clonal T-LGL diappeared
January 23, 2025 at 4:01 AM
Answer: T-LGL clone. Often donor in origin
- Associated with neutropenia.
- Can be clonal
- rule out viral reactivations (EBV, CMV etc)
- I often treat (in neutropenics) 60mg pred x 10-14days [no taper]
In this patients, post pred the clonal T-LGL diappeared
- Associated with neutropenia.
- Can be clonal
- rule out viral reactivations (EBV, CMV etc)
- I often treat (in neutropenics) 60mg pred x 10-14days [no taper]
In this patients, post pred the clonal T-LGL diappeared
People wonder why physicians #burnout
Evidence below:
Plus do you are expected to do more:
- research
- administration
- teaching
- nonsense satisfaction score (FYI patients want doctors to talk to them. How do you do that when you are double triple booked???)
Evidence below:
Plus do you are expected to do more:
- research
- administration
- teaching
- nonsense satisfaction score (FYI patients want doctors to talk to them. How do you do that when you are double triple booked???)
January 14, 2025 at 1:54 PM
People wonder why physicians #burnout
Evidence below:
Plus do you are expected to do more:
- research
- administration
- teaching
- nonsense satisfaction score (FYI patients want doctors to talk to them. How do you do that when you are double triple booked???)
Evidence below:
Plus do you are expected to do more:
- research
- administration
- teaching
- nonsense satisfaction score (FYI patients want doctors to talk to them. How do you do that when you are double triple booked???)
Current status of ADCs in #lymphoma #DLBCL. Loved developing this invited piece with two lymphoma rising stars @gulrayzahmed & @Taha_CancerDoc @MCWCancerCenter #lymsm www.tandfonline.com/doi/full/10....
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma
Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma (DLBC...
www.tandfonline.com
January 11, 2025 at 11:35 PM
Current status of ADCs in #lymphoma #DLBCL. Loved developing this invited piece with two lymphoma rising stars @gulrayzahmed & @Taha_CancerDoc @MCWCancerCenter #lymsm www.tandfonline.com/doi/full/10....
Our new @BMTCTN 1703 analysis busts a few myths:
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703
The BMT CTN 1703 phase III trial confirmed that graft-versus-host disease (GVHD) prophylaxis
with post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate
mofetil (MMF) result...
ascopubs.org
January 5, 2025 at 4:55 PM
Our new @BMTCTN 1703 analysis busts a few myths:
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...
- QOL improved with ptCY
- 🩸Cystitis not worse
- 2yr GRFS superior 42% vs 29%, p=0.001
- ptCY relapse NOT higher
@sghmd.bsky.social TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT
ascopubs.org/doi/10.1200/...
Playoff clinched @packers #GoPackGo
a green bay packers football player with the number 52 on his uniform
ALT: a green bay packers football player with the number 52 on his uniform
media.tenor.com
December 24, 2024 at 4:18 AM
Playoff clinched @packers #GoPackGo
Pink ODI for #breastcancer awareness 🇵🇰 vs. 🇿🇦 #GoPakGo @LubnaChaudhary1 🏏
December 22, 2024 at 7:19 PM
Pink ODI for #breastcancer awareness 🇵🇰 vs. 🇿🇦 #GoPakGo @LubnaChaudhary1 🏏
Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis. Recently saw my city #Lahore (Pakistan) and nearby #NewDehli breaking air pollution records ashpublications.org/blood/articl...
Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis
Key Points. Air pollution exposure is common, and may increase risk of developing blood clots.Greater long-term exposure to air pollution (i.e., PM2.5, NOx
ashpublications.org
December 17, 2024 at 1:54 AM
Air pollution is associated with increased risk of venous thromboembolism: the Multi-Ethnic Study of Atherosclerosis. Recently saw my city #Lahore (Pakistan) and nearby #NewDehli breaking air pollution records ashpublications.org/blood/articl...
Love seeing the Nivo-AVD story in older patients grow in Frontline c Hodgkin Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... congrats @PallawiTorkaMD
Need effective tools is frail/unfit/super elderly #lymsm
Need effective tools is frail/unfit/super elderly #lymsm
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma
PURPOSEWe conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine,
dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with
classical Hodgkin lymphom...
ascopubs.org
December 13, 2024 at 3:17 PM
Love seeing the Nivo-AVD story in older patients grow in Frontline c Hodgkin Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/... congrats @PallawiTorkaMD
Need effective tools is frail/unfit/super elderly #lymsm
Need effective tools is frail/unfit/super elderly #lymsm
Safety and Efficacy of Glofitamab for DLBCL in RW. It works, but like nearly all drugs, works less well in the streets #lymsm ashpublications.org/bloodadvance...
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study
Key Points. Glofitamab shows a 47% overall response rate (27% CR, 20% PR) and manageable safety in heavily pretreated r/r LBCL patients.Increased LDH is th
ashpublications.org
December 12, 2024 at 3:15 AM
Safety and Efficacy of Glofitamab for DLBCL in RW. It works, but like nearly all drugs, works less well in the streets #lymsm ashpublications.org/bloodadvance...
Impressive results of Dara vs. W&W in Smoldering #myeloma. Delay in progression; 📉mortality risk, favorable AE profile. ✅ Checks all the 📦📦 (just because HR SMM does not meet MM definition, doesn't mean it is not a PCD) congrats @vincentrk.bsky.social et al.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma | NEJM
Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a...
www.nejm.org
December 11, 2024 at 2:11 AM
Impressive results of Dara vs. W&W in Smoldering #myeloma. Delay in progression; 📉mortality risk, favorable AE profile. ✅ Checks all the 📦📦 (just because HR SMM does not meet MM definition, doesn't mean it is not a PCD) congrats @vincentrk.bsky.social et al.
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Reposted by Mehdi Hamadani
First selfie of #ASH24 with none other than @medihumdani.bsky.social 🩸 We are on our way to San Diego from Milwaukee! @ash-hematology.bsky.social
December 6, 2024 at 5:46 PM
First selfie of #ASH24 with none other than @medihumdani.bsky.social 🩸 We are on our way to San Diego from Milwaukee! @ash-hematology.bsky.social
Reposted by Mehdi Hamadani
December 3, 2024 at 12:17 PM
Much awaited ECOG 4151 results out. IMO definitely ends debate for autoHCT in MCL in MRD negative CR1. #PracticeChaning and congrats to my friend @timfenske in advancing patient care @MCWCancerCenter @ASH_hematology #ASH2025
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
Paper: Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Dise...
ash.confex.com
November 25, 2024 at 6:31 PM
Much awaited ECOG 4151 results out. IMO definitely ends debate for autoHCT in MCL in MRD negative CR1. #PracticeChaning and congrats to my friend @timfenske in advancing patient care @MCWCancerCenter @ASH_hematology #ASH2025
ash.confex.com/ash/2024/web...
ash.confex.com/ash/2024/web...
University of Bologna, oldest in the world and its iconic Anatomical Theatre
November 20, 2024 at 7:52 PM
University of Bologna, oldest in the world and its iconic Anatomical Theatre
Super interesting real world study showing superiority of Axi-cel over liso-cel after matching. Off trial, I uniformly use axi-cel regardless of patient characteristics. IMO reliability and turn around matters!! #lymsm ashpublications.org/bloodadvance...
A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma
Key Points. Axi-cel and liso-cel had similar outcomes, though when accounting for differences in risk factors, axi-cel was associated with superior PFS.We
ashpublications.org
November 19, 2024 at 2:09 PM
Super interesting real world study showing superiority of Axi-cel over liso-cel after matching. Off trial, I uniformly use axi-cel regardless of patient characteristics. IMO reliability and turn around matters!! #lymsm ashpublications.org/bloodadvance...
Reposted by Mehdi Hamadani
@szusmani.bsky.social
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
November 18, 2024 at 6:56 PM
@szusmani.bsky.social
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
At PCUH(Pakistan PSH).....Will try to get his full presentation very soon.thoughts provoking talk...we are blessed ,
Impressive 3-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies. Median PFS 24mons, median OS NR #lymsm ashpublications.org/blood/articl...
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Key Points. Three-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies showed long-lasting remissions and meaningful survival outcomesManagea
ashpublications.org
November 19, 2024 at 12:32 AM
Impressive 3-year follow-up of mosunetuzumab in R/R FL after ≥2 prior therapies. Median PFS 24mons, median OS NR #lymsm ashpublications.org/blood/articl...
Reposted by Mehdi Hamadani
🚨Capstan Therapeutics Preclinical Data on In Vivo CAR-T
-engineering of CD8+ CAR T cells, profound B cell depletion in blood & tissues, repopulation w predominantly naïve B cells in NHP's
-without need for lymphodepleting chemotherapy
-plans to clinic mid 2025
www.capstantx.com/posts/capsta...
-engineering of CD8+ CAR T cells, profound B cell depletion in blood & tissues, repopulation w predominantly naïve B cells in NHP's
-without need for lymphodepleting chemotherapy
-plans to clinic mid 2025
www.capstantx.com/posts/capsta...
Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024 - Capstan Therapeutics
Capstan Therapeutics Presents Preclinical Data on Lead In Vivo CAR-T Candidate, CPTX2309, at American College of Rheumatology (ACR) Convergence 2024
www.capstantx.com
November 18, 2024 at 12:37 PM
🚨Capstan Therapeutics Preclinical Data on In Vivo CAR-T
-engineering of CD8+ CAR T cells, profound B cell depletion in blood & tissues, repopulation w predominantly naïve B cells in NHP's
-without need for lymphodepleting chemotherapy
-plans to clinic mid 2025
www.capstantx.com/posts/capsta...
-engineering of CD8+ CAR T cells, profound B cell depletion in blood & tissues, repopulation w predominantly naïve B cells in NHP's
-without need for lymphodepleting chemotherapy
-plans to clinic mid 2025
www.capstantx.com/posts/capsta...
Reposted by Mehdi Hamadani
Saad Usmani, MD, shared exciting FIRST results from CEPHEUS study of a Dara quad in transplant-ineligible/transplant-deferred NDMM.
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24
September 28, 2024 at 10:33 AM
Saad Usmani, MD, shared exciting FIRST results from CEPHEUS study of a Dara quad in transplant-ineligible/transplant-deferred NDMM.
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24
Quads continue to improve outcomes & take spotlight in frontline induction. @szusmani.bsky.social #IMS24